N-[2-(1H-indol-3-yl)ethyl]-2,4-dinitroaniline

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(1H-indol-3-yl)ethyl]-2,4-dinitroaniline
• 化学式: C16H14N4O4
• mdl: MFCD00716925
• 分子量: 326.31
• InChiKey: DVMBDPMSHUSHMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  色胺 、 碳酸氢钠 、 、 2,4-二硝基氟苯 在 desired product 、 氯仿 、 silica 作用下， 以 水 、 乙醇 为溶剂， 反应 2.0h， 生成 N-[2-(1H-indol-3-yl)ethyl]-2,4-dinitroaniline
  参考文献：
  名称：

  Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them

  摘要：

  本发明涉及使用新型取代色胺和相关衍生物治疗多种医疗状况，例如前列腺问题、阳痿、心血管疾病、中枢神经系统和精神障碍（如睡眠障碍、癫痫和其他惊厥性障碍、焦虑、神经退行性疾病）、基于生物钟的障碍（如时差反应、延迟睡眠综合症、轮班工作相关的睡眠障碍或季节性情感障碍）、内分泌指标、肿瘤状况、与衰老有关的状况、眼科疾病、集群头痛和偏头痛以及体重增加障碍。

  公开号：

  US20050020664A1

文献信息

• Derivating of tryptamine and analogous componds and pharmaceutical formulations containing them
  申请人：——

  公开号：US20040029950A1

  公开（公告）日：2004-02-12

  This invention relates to novel substituted tryptamines and related derivatives, as well as pharmaceutical compositions formulated therefrom. These compounds, compositions and their salts can be used in the manufacture of medicaments for interacting with the melatoninergic system. These compounds and conditions can be used for treating several types of medical conditions, such as central nervous system and psychiatric disorders (sleep disorders, epilepsy and other convulsive disorders, anxiety, neurodegenerative diseases), chronobiological-based disorders (jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder), neoplastic conditions, and conditions associated with senescence.

  本发明涉及新型取代色胺和相关衍生物，以及从中制备的药物组合物。这些化合物、组合物及其盐可用于制造与褪黑激素系统相互作用的药物。这些化合物和条件可用于治疗多种类型的医疗状况，如中枢神经系统和精神障碍（睡眠障碍、癫痫和其他惊厥性障碍、焦虑、神经退行性疾病）、以生物钟为基础的障碍（时差反应、延迟睡眠综合症、倒班工作、季节性情感障碍）、肿瘤状况以及与衰老相关的状况。
• Derivating of tryptamine and analogous compounds and pharmaceutical formulations containing them
  申请人：Neurim Pharmaceuticals (1991) Ltd.

  公开号：US06780884B2

  公开（公告）日：2004-08-24

  This invention relates to novel substituted tryptamines and related derivatives, as well as pharmaceutical compositions formulated therefrom. These compounds, compositions and their salts can be used in the manufacture of medicaments for interacting with the melatoninergic system. These compounds and conditions can be used for treating several types of medical conditions, such as central nervous system and psychiatric disorders (sleep disorders, epilepsy and other convulsive disorders, anxiety, neurodegenerative diseases), chronobiological-based disorders (jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder), neoplastic conditions, and conditions associated with senescence.

  该发明涉及新型取代色胺和相关衍生物，以及由此制备的药物组成物。这些化合物，组成物及其盐可用于制造用于与褪黑素系统相互作用的药物。这些化合物和条件可用于治疗多种类型的医疗状况，如中枢神经系统和精神障碍（睡眠障碍，癫痫和其他惊厥性障碍，焦虑，神经退行性疾病），生物钟基础障碍（时差反应，延迟睡眠综合症，轮班工作，季节性情感障碍），肿瘤疾病和与衰老有关的疾病。
• DERIVATIVES OF TRYPTAMINE AND ANALOGOUS COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM
  申请人：NEURIM PHARMACEUTICALS (1991) LIMITED

  公开号：EP1331935A2

  公开（公告）日：2003-08-06
• EP1331935A4
  申请人：——

  公开号：EP1331935A4

  公开（公告）日：2004-12-01
• LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT
  申请人：Chi Mei Corporation

  公开号：US20160024386A1

  公开（公告）日：2016-01-28

  A liquid crystal alignment agent capable of forming a liquid crystal alignment film having good ultraviolet reliability, the liquid crystal alignment film, and a liquid crystal display element having the same are provided. The liquid crystal alignment agent includes a polymer (A) and a solvent (B). The polymer (A) is obtained by reacting a mixture. The mixture includes a tetracarboxylic dianhydride component (a) and a diamine component (b). The diamine component (b) includes a diamine compound (b-1) represented by formula (1), a diamine compound (b-2) represented by formula (2), and a diamine compound (b-3) having a structure represented by formula (3).